TPT Nanomicelles Reduce Retinal Inflammation in a Mouse Uveitis Model
Published in Immunology, Journals, Nanomedicine.
Published October 26, 2026.
An experimental nanomaterial reduced retinal inflammation in mice with autoimmune uveitis, according to research published October 23 in the Journal of Translational Medicine. Chao Wu and colleagues investigated TPT nanomicelles, abbreviated TPTN, through laboratory experiments and a mouse disease model.
The material scavenged reactive oxygen species and showed low cytotoxicity under the tested laboratory conditions. In mice, treatment reduced retinal inflammation, limited disruption of the blood-retinal barrier and suppressed activation of microglia, immune cells involved in retinal inflammatory responses.
Proteomic and biochemical analyses implicated reduced JAK2–STAT1 signaling. A separate experiment using the JAK2 inhibitor fedratinib reproduced several effects, supporting involvement of this pathway. That comparison strengthens the mechanistic interpretation without proving that all effects arise through one pathway.
Evidence limits: These are preclinical findings, not results from patients with uveitis. Low toxicity in the reported experiments does not establish long-term safety in humans, and clinical benefit remains untested. The journal has released the accepted paper early, with further editorial changes possible.
Source: Wu et al., Journal of Translational Medicine, October 23, 2026.